Hikma partners with Perrigo

Hikma will market a range of Perrigo consumer healthcare products in the Middle East and North Africa (MENA) region after signing a licensing and distribution agreement with Perrigo’s Omega Pharma OTC affiliate. Under the terms of the deal, Hikma will have the “exclusive right to licence and distribute more than 30 consumer healthcare products – including Davitamon, Prevalin, XLS Medical, Dermalex and Paranix–in all its MENA markets, with the exception of current arrangements in place”.

Hikma will market a range of Perrigo consumer healthcare products in the Middle East and North Africa (MENA) region after signing a licensing and distribution agreement with Perrigo’s Omega Pharma OTC affiliate. Under the terms of the deal, Hikma will have the “exclusive right to licence and distribute more than 30 consumer healthcare products – including Davitamon, Prevalin, XLS Medical, Dermalex and Paranix–in all its MENA markets, with the exception of current arrangements in place”.

The Jordanian firm said it would aim to work with Perrigo’s existing partners in the MENA region “to broaden sales...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Archive

ADHD Medications and Cardiovascular Effects: New Data Revealed. (A Comprehensive Evaluation of Emerging Clinical and Epidemiological Evidence on the Cardiovascular Effects Associated with Prescribed Medications for Attention Deficit Hyperactivity Disorder) - Clone - Clone

 
• By 

A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.

Testing-Rising

 
• By 

Testing-Rising xxxx

bhvyuguig

lnkbkb

test 1

test 1

More from Generics Bulletin

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C11

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C10

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C9

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.